Advertisement
UK markets closed

  • FTSE 100

    8,146.86
    -16.81 (-0.21%)
     

  • FTSE 250

    20,120.36
    -75.59 (-0.37%)
     

  • AIM

    776.04
    -4.39 (-0.56%)
     

  • GBP/EUR

    1.1845
    -0.0034 (-0.29%)
     

  • GBP/USD

    1.2686
    -0.0075 (-0.59%)
     

  • Bitcoin GBP

    52,291.82
    -365.30 (-0.69%)
     

  • CMC Crypto 200

    1,400.55
    -17.32 (-1.22%)
     

  • S&P 500

    5,431.60
    -2.14 (-0.04%)
     

  • DOW

    38,589.16
    -57.94 (-0.15%)
     

  • CRUDE OIL

    78.49
    -0.13 (-0.17%)
     

  • GOLD FUTURES

    2,348.40
    +30.40 (+1.31%)
     

  • NIKKEI 225

    38,814.56
    +94.09 (+0.24%)
     

  • HANG SENG

    17,941.78
    -170.85 (-0.94%)
     

  • DAX

    18,002.02
    -263.66 (-1.44%)
     

  • CAC 40

    7,503.27
    -204.75 (-2.66%)
     
Property:

10 sustainable properties to boost your eco-credentials

You can make a long-term commitment to protect the planet by buying a house that's eco-friendly

Zealand Pharma conference call on May 16 at 2pm CET (8am ET) to present first quarter 2024 financial results

Zealand Pharma
·2-min read
Zealand Pharma
Zealand Pharma

Press Release – No. 4 / 2024

Zealand Pharma conference call on May 16 at 2pm CET (8am ET) to present first quarter 2024 financial results

Copenhagen, Denmark, May 9, 2024 – Zealand Pharma A/S (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, announced that it will host a conference call on May 16, 2024, at 2:00 pm CET (8:00 am ET) following the announcement of financial results for the first quarter of 2024.

Presenting during the call will be President and Chief Executive Officer, Adam Steensberg; Chief Financial Officer, Henriette Wennicke; and Chief Medical Officer, David Kendall. The presentation will be followed by a Q&A session.

ADVERTISEMENT

The live listen-only audio webcast of the call and accompanying slide presentation will be accessible at https://edge.media-server.com/mmc/p/ee4aippx. To receive telephone dial-in information and a unique personal access PIN, please register at https://register.vevent.com/register/BI3bf842a335dd49a79930cafce733506c. Participants are advised to register for the call or webcast approximately 10 minutes before the start. A recording of the event will be available following the call on the Investor section of Zealand’s website at https://www.zealandpharma.com/events/.

About Zealand Pharma A/S

Zealand Pharma A/S (Nasdaq: ZEAL) ("Zealand") is a biotechnology company focused on the discovery and development of peptide-based medicines. More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market and three candidates are in late-stage development. The company has development and partnerships with a number of pharma companies as well as commercial partnerships for its marketed products.

Zealand was founded in 1998 and is headquartered in Copenhagen, Denmark, with a presence in the U.S. For more information about Zealand’s business and activities, please visit www.zealandpharma.com.

Contacts:

Adam Lange (Investors)

Investor Relations Officer

Zealand Pharma

alange@zealandpharma.com

 

Anna Krassowska, PhD (Investors and Media)

Vice President, Investor Relations & Corporate Communications

Zealand Pharma

akrassowska@zealandpharma.com